A ruling against skinny labeling could push back generic drug competition by years, with billions in costs passed on to ...

The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the ...

Here’s why the case matters: As soon as a generic version of a brand-name drug comes to market, its price typically drops by half. Within 10 years, by more than 75%. Meaning: the sooner we have access ...